EU regulator starts safety review of CAR-T cancer cell therapies

Written By :  Ruchika Sharma
Medically Reviewed By :  Dr. Kamal Kant Kohli
Published On 2024-01-15 03:30 GMT   |   Update On 2024-03-27 08:46 GMT
Advertisement

The European Union's drug watchdog has said it had started a review into the safety risks associated with cancer cell therapies made by companies such as Novartis and Gilead Sciences.

The treatment for different types of blood cancer, known as chimeric antigen receptor T-cell therapies or CAR-T, generally involves extracting disease-fighting white blood cells known as T-cells from a patient, re-engineering them to attack cancer and infusing them back into the body.
Advertisement
The European Medicines Agency's Pharmacovigilance Risk Assessment Committee (PRAC) said it will review data on secondary malignancies or the development of an additional type of cancer related to the T-cells, after patients use the medicines.
The U.S. Food and Drug Administration is also investigating six of these therapies approved in the EU.
These include Bristol Myers Squibb's Breyanzi and its partnered therapy, Abecma, with 2seventy bio. J&J unit Janssen and Legend Biotech's Carvykti, Novartis' Kymriah, and Gilead unit Kite's Tecartus and Yescarta are also a part of the review, the EMA said.
Tags:    

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News